Ligand Pharma (LGND)
304.26
-1.21 (0.40%)
Upcoming Events
Latest Headlines
Form S-8 LIGAND PHARMACEUTICALS
July 22, 2026 4:53 PM - SEC Filing
Citi resumes Ligand Pharma coverage with Buy rating, $387 target
July 21, 2026 5:01 AM - StreetInsider
Ligand Pharma (LGND) PT Raised to $335 at Benchmark as XOMA Royalty Cash Acquisition Completed
July 16, 2026 7:57 AM - StreetInsider
Ligand Pharma (LGND) PT Raised to $340 at RBC Capital
July 15, 2026 6:25 AM - StreetInsider
Form 8-K LIGAND PHARMACEUTICALS For: Jul 14
July 14, 2026 9:20 AM - SEC Filing
Ligand completes acquisition of XOMA Royalty at $39 per share
July 14, 2026 9:01 AM - StreetInsider
Ligand completes $739M acquisition of XOMA Royalty
July 14, 2026 9:00 AM - StreetInsider
XOMA Royalty Announces Closing of Its Acquisition by Ligand
July 14, 2026 9:00 AM - StreetInsider
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
July 14, 2026 9:00 AM - StreetInsider
Ligand Pharma (LGND) PT Raised to $388 at BofA Securities
July 9, 2026 5:13 AM - StreetInsider
Ligand Pharma (LGND) PT Raised to $332 at Stifel as Xoma Asset Acquisition Announced
July 8, 2026 7:22 AM - StreetInsider
Form 4 LIGAND PHARMACEUTICALS For: Jun 30 Filed by: Reardon Andrew
July 6, 2026 5:11 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 30 Filed by: Espinoza Octavio
July 6, 2026 5:11 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 30 Filed by: Davis Todd C
July 6, 2026 5:10 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: Reardon Andrew
July 1, 2026 4:57 PM - SEC Filing
Form 8-K LIGAND PHARMACEUTICALS For: Jun 25
June 25, 2026 5:01 PM - SEC Filing
Ligand closes $700M convertible notes offering due 2031
June 25, 2026 4:01 PM - StreetInsider
Ligand Announces Closing of Convertible Senior Notes Offering
June 25, 2026 4:01 PM - Globe NewsWire
Ligand prices $625M convertible notes due 2031 at 0% interest
June 23, 2026 4:00 AM - StreetInsider
Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering
June 23, 2026 4:00 AM - Globe NewsWire
Form 8-K LIGAND PHARMACEUTICALS For: Jun 22
June 22, 2026 7:12 AM - SEC Filing
Ligand plans $550M convertible notes offering due 2031
June 22, 2026 7:01 AM - StreetInsider
Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031
June 22, 2026 7:00 AM - Globe NewsWire
Form 4 LIGAND PHARMACEUTICALS For: Jun 16 Filed by: Sabba Stephen L
June 18, 2026 8:38 AM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: Sabba Stephen L
June 16, 2026 4:31 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 12 Filed by: Haas Jason
June 15, 2026 9:07 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 05 Filed by: Aryeh Jason
June 12, 2026 5:27 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 10 Filed by: LAMATTINA JOHN L
June 12, 2026 5:26 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: Haas Jason
June 12, 2026 4:11 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: Aryeh Jason
June 11, 2026 12:22 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: Aryeh Jason
June 10, 2026 4:45 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: LAMATTINA JOHN L
June 10, 2026 4:08 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: Aryeh Jason
June 10, 2026 1:41 PM - SEC Filing
Ligand Announces 2026 Investor Day in New York City
June 10, 2026 7:00 AM - Globe NewsWire
Form 4 LIGAND PHARMACEUTICALS For: Jun 05 Filed by: Zimmermann Martine
June 9, 2026 7:42 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 05 Filed by: Sabba Stephen L
June 9, 2026 7:42 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 05 Filed by: LAMATTINA JOHN L
June 9, 2026 7:41 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 05 Filed by: KOZARICH JOHN W
June 9, 2026 7:40 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 05 Filed by: Haas Jason
June 9, 2026 7:36 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 05 Filed by: Gray Nancy Ryan
June 9, 2026 7:35 PM - SEC Filing
Form 8-K LIGAND PHARMACEUTICALS For: Jun 05
June 9, 2026 4:03 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: Jun 01 Filed by: Reardon Andrew
June 2, 2026 6:22 PM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: May 27 Filed by: Espinoza Octavio
May 28, 2026 7:43 PM - SEC Filing
Ligand to Participate in June Investor Conferences
May 27, 2026 4:01 PM - Globe NewsWire
Form DEFA14A LIGAND PHARMACEUTICALS
May 18, 2026 9:03 AM - SEC Filing
Form 8-K LIGAND PHARMACEUTICALS For: May 16
May 18, 2026 9:02 AM - SEC Filing
Form 4 LIGAND PHARMACEUTICALS For: May 01 Filed by: KOZARICH JOHN W
May 14, 2026 9:09 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: KOZARICH JOHN W
May 13, 2026 4:09 PM - SEC Filing
Form 144 LIGAND PHARMACEUTICALS Filed by: KOZARICH JOHN W
May 12, 2026 5:45 PM - SEC Filing
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
May 12, 2026 4:18 PM - Globe NewsWire
Form 10-Q LIGAND PHARMACEUTICALS For: Mar 31
May 8, 2026 4:15 PM - SEC Filing
Ligand Pharma (LGND) PT Raised to $262 at RBC Capital
May 8, 2026 7:34 AM - StreetInsider
Ligand Pharma (LGND) Misses Q1 EPS by 21c
May 7, 2026 7:42 AM - StreetInsider
Form 8-K LIGAND PHARMACEUTICALS For: May 07
May 7, 2026 7:04 AM - SEC Filing
Ligand Reports First Quarter 2026 Financial Results
May 7, 2026 7:01 AM - Globe NewsWire
Orchestra BioMed receives $15 million from Ligand under financing agreement
May 6, 2026 8:01 AM - StreetInsider
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
May 6, 2026 8:01 AM - Globe NewsWire
Ligand to Participate in May Investor Conferences
May 5, 2026 4:01 PM - Globe NewsWire
Form 4 LIGAND PHARMACEUTICALS For: May 01 Filed by: Reardon Andrew
May 4, 2026 8:20 PM - SEC Filing
Oppenheimer Assumes Ligand Pharma (LGND) at Outperform
May 4, 2026 8:17 AM - StreetInsider
Form 144 LIGAND PHARMACEUTICALS Filed by: KOZARICH JOHN W
May 1, 2026 4:17 PM - SEC Filing
Form SCHEDULE 13G LIGAND PHARMACEUTICALS Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC
May 1, 2026 9:22 AM - SEC Filing
Form SCHEDULE 13G LIGAND PHARMACEUTICALS Filed by: VANGUARD CAPITAL MANAGEMENT LLC
May 1, 2026 9:12 AM - SEC Filing
Form 8-K LIGAND PHARMACEUTICALS For: Apr 24
April 30, 2026 4:41 PM - SEC Filing
Ligand Pharma (LGND) PT Raised to $289 at H.C. Wainwright
April 30, 2026 6:51 AM - StreetInsider
Ligand Pharma (LGND) PT Raised to $330 at Craig-Hallum
April 28, 2026 11:03 AM - StreetInsider
Form DEFA14A LIGAND PHARMACEUTICALS
April 28, 2026 6:07 AM - SEC Filing
Ligand Pharma (LGND) PT Raised to $252 at RBC Capital
April 28, 2026 5:06 AM - StreetInsider
Ligand Pharma (LGND) PT Raised to $260 at BofA Securities
April 27, 2026 2:55 PM - StreetInsider
Ligand Pharma (LGND) PT Raised to $255 at Stifel
April 27, 2026 1:56 PM - StreetInsider
Form DEFA14A LIGAND PHARMACEUTICALS
April 27, 2026 9:41 AM - SEC Filing
Form 8-K LIGAND PHARMACEUTICALS For: Apr 27
April 27, 2026 9:30 AM - SEC Filing
Ligand to acquire XOMA Royalty for $739 million in cash deal
April 27, 2026 7:01 AM - StreetInsider
Ligand to acquire XOMA Royalty for $739 million in cash deal
April 27, 2026 7:00 AM - StreetInsider
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
April 27, 2026 7:00 AM - Globe NewsWire
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
April 27, 2026 7:00 AM - Globe NewsWire
Ligand Pharma (LGND) to buy Xoma for ~$740M - WSJ
April 27, 2026 6:16 AM - StreetInsider
Full Article List
